Barclays
PGNX

Barclays’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Barclays’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,500
Closed -$25K – 6541
2020
Q1 		$25K Sell
6,500
-7,700
-54% -$33.2K ﹤0.01% 5571
2019
Q4 		$72K Sell
14,200
-2,400
-14% -$12.7K ﹤0.01% 5625
2019
Q3 		$84K Buy
16,600
+11,300
+213% +$56.4K ﹤0.01% 5608
2019
Q2 		$33K Buy
5,300
+3,500
+194% +$16.9K ﹤0.01% 6272
2019
Q1 		$8K Sell
1,800
-4,900
-73% -$22.2K ﹤0.01% 6631
2018
Q4 		$28K Sell
6,700
-5,200
-44% -$26.5K ﹤0.01% 5762
2018
Q3 		$75K Buy
11,900
+4,200
+55% +$32.3K ﹤0.01% 5804
2018
Q2 		$62K Sell
7,700
-12,200
-61% -$93.1K ﹤0.01% 5538
2018
Q1 		$148K Buy
19,900
+13,000
+188% +$86.4K ﹤0.01% 5086
2017
Q4 		$41K Sell
6,900
-1,500
-18% -$9.11K ﹤0.01% 5877
2017
Q3 		$62K Buy
8,400
+5,000
+147% +$31.8K ﹤0.01% 5231
2017
Q2 		$23K Buy
3,400
+900
+36% +$6.64K ﹤0.01% 5747
2017
Q1 		$24K Buy
2,500
+1,700
+213% +$17K ﹤0.01% 5729
2016
Q4 		$7K Sell
800
-11,100
-93% -$82K ﹤0.01% 6050
2016
Q3 		$75K Buy
11,900
+10,000
+526% +$60.5K ﹤0.01% 4719
2016
Q2 		$8K Buy
1,900
+1,400
+280% +$6.76K ﹤0.01% 5628
2016
Q1 		$2K Buy
+500
New +$2.23K ﹤0.01% 5912
2015
Q3 		– Sell
-83,600
Closed -$585K – 7172
2015
Q2 		$585K Buy
83,600
+100
+0.1% +$605 ﹤0.01% 3345
2015
Q1 		$418K Buy
83,500
+79,400
+1,937% +$500K ﹤0.01% 3766
2014
Q4 		$29K Buy
4,100
+1,900
+86% +$11.4K ﹤0.01% 6096
2014
Q3 		$11K Sell
2,200
-3,300
-60% -$16.4K ﹤0.01% 6847
2014
Q2 		$22K Sell
5,500
-9,700
-64% -$37K ﹤0.01% 6465
2014
Q1 		$61K Buy
15,200
+11,800
+347% +$60.3K ﹤0.01% 5844
2013
Q4 		$17K Sell
3,400
-3,000
-47% -$13.2K ﹤0.01% 6801
2013
Q3 		$32K Sell
6,400
-5,200
-45% -$28.2K ﹤0.01% 6306
2013
Q2 		$52K Buy
+11,600
New +$52.1K ﹤0.01% 6283

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Barclays's PGNX Position: Q2 2020 in Review

Barclays sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 73,821 shares — an estimated $280K sold.

Barclays first reported a position in PGNX in Q2 2013 and held it in 27 quarters. The position peaked at $2.12M in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Barclays reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Barclays sold 73,821 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $280K.
  • Barclays first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 27 quarters.
  • Barclays's Progenics Pharmaceuticals Inc position peaked at $2.12M in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.